Q3-osavuosiraportti
Äänite tulossa
2 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
463 524
Myynti
Määrä
779 909
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 425 | - | - | ||
| 500 | - | - | ||
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - |
Ylin
0,478VWAP
Alin
0,325VaihtoMäärä
69,3 172 950 879
VWAP
Ylin
0,478Alin
0,325VaihtoMäärä
69,3 172 950 879
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 23.10. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2024 Yhtiökokous | 6.5. | |
| 2025 Q1-osavuosiraportti | 29.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
48 min sitten·Why this sharp drop? The report was basically quite positive. Is it just a take-home pay bonus for the impatient, or is someone reading something I'm not?🤔
18 min sitten·There was probably unrealistically high optimism before the report and it presented a realistic, yet positive conclusion for a phase 2a research report. I don't think many of those who speculated on this stock were thinking long-term and therefore had to call their own shots when the report was not predominantly positive and revolutionary. Nevertheless, the drug is qualified for the next step in the research process, so if you choose to have faith in the drug and are optimistic about the future of the company, it is worth investing now. But if you are looking for short-term gain, this is probably not a good investment for now.
19 t sitten·Possibly, maybe, or rather nothing. It's better to take it in stride. As has worked for 100,000 years.
20 t sitten · Muokattu·Just glad that people are so stupid sometimes and can't distinguish between unrealistic hopes and actual results. There are no pharmaceutical companies that only work with constant super tailwinds. That's what reality actually looks like. Phase 2 is, among other things, for experimenting, learning, and building a drug on. Constantly hoping for dream scenarios is hugely illogical. The study results were actually very good and positive. With a 50mg dose, and maybe possibly 75mg or 100mg, the effect will be highly significant in those groups that have moderate and real needs for the drug. The fact that the side effects are so few means the market underestimates the value of enormously. Grateful to continue making money on good opportunities like this one. Sit in the boat. Have ice in your stomach. Keep the shit. So maybe you'll actually stop saying, don't understand how everyone can be so lucky and have their shares double in value 10 times. It's those who hold on for a very long time who succeed in doing just that. The company will succeed in further promoting the drug, especially now that the results have been seen. I have been trading stocks for about 20 years. I make a lot of money on most of them by day trading. I choose to keep a few individual stocks for the long term and not sell. Dicot is guaranteed to be such a stock. It is not often that you find such situations in the market. I myself have only tripled my stocks today. And I promise everyone who sells because they have dreamed of lots of scenarios that I will continue to make money on stocks, even after 20 years.
11 t sitten·Pfg, I completely agree with your reasoning. I also refer to the post on July 18th that I liked, where you describe the importance of giving companies like Dicot time to develop. I have chosen to double and am considering increasing it further when the price stabilizes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
Äänite tulossa
2 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 48 min sitten·Why this sharp drop? The report was basically quite positive. Is it just a take-home pay bonus for the impatient, or is someone reading something I'm not?🤔18 min sitten·There was probably unrealistically high optimism before the report and it presented a realistic, yet positive conclusion for a phase 2a research report. I don't think many of those who speculated on this stock were thinking long-term and therefore had to call their own shots when the report was not predominantly positive and revolutionary. Nevertheless, the drug is qualified for the next step in the research process, so if you choose to have faith in the drug and are optimistic about the future of the company, it is worth investing now. But if you are looking for short-term gain, this is probably not a good investment for now.
- 19 t sitten·Possibly, maybe, or rather nothing. It's better to take it in stride. As has worked for 100,000 years.
- 20 t sitten · Muokattu·Just glad that people are so stupid sometimes and can't distinguish between unrealistic hopes and actual results. There are no pharmaceutical companies that only work with constant super tailwinds. That's what reality actually looks like. Phase 2 is, among other things, for experimenting, learning, and building a drug on. Constantly hoping for dream scenarios is hugely illogical. The study results were actually very good and positive. With a 50mg dose, and maybe possibly 75mg or 100mg, the effect will be highly significant in those groups that have moderate and real needs for the drug. The fact that the side effects are so few means the market underestimates the value of enormously. Grateful to continue making money on good opportunities like this one. Sit in the boat. Have ice in your stomach. Keep the shit. So maybe you'll actually stop saying, don't understand how everyone can be so lucky and have their shares double in value 10 times. It's those who hold on for a very long time who succeed in doing just that. The company will succeed in further promoting the drug, especially now that the results have been seen. I have been trading stocks for about 20 years. I make a lot of money on most of them by day trading. I choose to keep a few individual stocks for the long term and not sell. Dicot is guaranteed to be such a stock. It is not often that you find such situations in the market. I myself have only tripled my stocks today. And I promise everyone who sells because they have dreamed of lots of scenarios that I will continue to make money on stocks, even after 20 years.11 t sitten·Pfg, I completely agree with your reasoning. I also refer to the post on July 18th that I liked, where you describe the importance of giving companies like Dicot time to develop. I have chosen to double and am considering increasing it further when the price stabilizes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
463 524
Myynti
Määrä
779 909
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 425 | - | - | ||
| 500 | - | - | ||
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - |
Ylin
0,478VWAP
Alin
0,325VaihtoMäärä
69,3 172 950 879
VWAP
Ylin
0,478Alin
0,325VaihtoMäärä
69,3 172 950 879
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 23.10. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2024 Yhtiökokous | 6.5. | |
| 2025 Q1-osavuosiraportti | 29.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
Äänite tulossa
2 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 23.10. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2024 Yhtiökokous | 6.5. | |
| 2025 Q1-osavuosiraportti | 29.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 48 min sitten·Why this sharp drop? The report was basically quite positive. Is it just a take-home pay bonus for the impatient, or is someone reading something I'm not?🤔18 min sitten·There was probably unrealistically high optimism before the report and it presented a realistic, yet positive conclusion for a phase 2a research report. I don't think many of those who speculated on this stock were thinking long-term and therefore had to call their own shots when the report was not predominantly positive and revolutionary. Nevertheless, the drug is qualified for the next step in the research process, so if you choose to have faith in the drug and are optimistic about the future of the company, it is worth investing now. But if you are looking for short-term gain, this is probably not a good investment for now.
- 19 t sitten·Possibly, maybe, or rather nothing. It's better to take it in stride. As has worked for 100,000 years.
- 20 t sitten · Muokattu·Just glad that people are so stupid sometimes and can't distinguish between unrealistic hopes and actual results. There are no pharmaceutical companies that only work with constant super tailwinds. That's what reality actually looks like. Phase 2 is, among other things, for experimenting, learning, and building a drug on. Constantly hoping for dream scenarios is hugely illogical. The study results were actually very good and positive. With a 50mg dose, and maybe possibly 75mg or 100mg, the effect will be highly significant in those groups that have moderate and real needs for the drug. The fact that the side effects are so few means the market underestimates the value of enormously. Grateful to continue making money on good opportunities like this one. Sit in the boat. Have ice in your stomach. Keep the shit. So maybe you'll actually stop saying, don't understand how everyone can be so lucky and have their shares double in value 10 times. It's those who hold on for a very long time who succeed in doing just that. The company will succeed in further promoting the drug, especially now that the results have been seen. I have been trading stocks for about 20 years. I make a lot of money on most of them by day trading. I choose to keep a few individual stocks for the long term and not sell. Dicot is guaranteed to be such a stock. It is not often that you find such situations in the market. I myself have only tripled my stocks today. And I promise everyone who sells because they have dreamed of lots of scenarios that I will continue to make money on stocks, even after 20 years.11 t sitten·Pfg, I completely agree with your reasoning. I also refer to the post on July 18th that I liked, where you describe the importance of giving companies like Dicot time to develop. I have chosen to double and am considering increasing it further when the price stabilizes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
463 524
Myynti
Määrä
779 909
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 425 | - | - | ||
| 500 | - | - | ||
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - |
Ylin
0,478VWAP
Alin
0,325VaihtoMäärä
69,3 172 950 879
VWAP
Ylin
0,478Alin
0,325VaihtoMäärä
69,3 172 950 879
Välittäjätilasto
Dataa ei löytynyt